Nivolumab biosimilar(Xbrane)

纳武利尤单抗生物类似药（Xbrane）

Report date: 2025/02/19 10:16:08

Base Information

Drug NameNivolumab biosimilar(Xbrane)
Drug Alias NameXdivane
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsUrinary Bladder NeoplasmsLung NeoplasmsSkin Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXbrane Biopharma Ab
China Registration ClassN/A

Develop Information

Active CompaniesXbrane Biopharma AbIntas Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsLung NeoplasmsSkin Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A